skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome

Abstract

Purpose: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. Methods and Materials: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score {>=}6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatment diagnostic tumor biopsies using a semiquantitative immunohistochemical scoring system. The results were analyzed in relation to clinicopathologic factors and patient outcome including biochemical failure and disease-specific mortality. Results: High VEGF expression was associated with a poor prognosis: in univariate log rank analysis, VEGF was the only significant prognostic factor for disease-specific survival (p = 0.035). High VEGF expression also associated with increased Gleason score (p = 0.02), but not posttreatment biochemical failure. Conclusion: High tumor expression of VEGF identified patients at high risk of failure of treatment with radiotherapy. These patients might benefit from additional treatment approaches incorporating anti-angiogenic ormore » hypoxia-specific agents.« less

Authors:
 [1];  [2];  [3];  [4];  [5];  [6];  [3];  [7]
  1. Department of Pharmacy and Pharmaceutical Sciences, Coupland III, University of Manchester, Oxford Road, Manchester (United Kingdom)
  2. (United Kingdom)
  3. Department of Clinical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester (United Kingdom)
  4. Department of Histopathology, University of Manchester, Christie Hospital NHS Trust, Manchester (United Kingdom)
  5. Department of Medical Statistics, University of Manchester, Christie Hospital NHS Trust, Manchester (United Kingdom)
  6. Academic Department of Radiation Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester (United Kingdom)
  7. Department of Pharmacy and Pharmaceutical Sciences, Coupland III, University of Manchester, Oxford Road, Manchester (United Kingdom). E-mail: ian.j.stratford@manchester.ac.uk
Publication Date:
OSTI Identifier:
20850298
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 67; Journal Issue: 1; Other Information: DOI: 10.1016/j.ijrobp.2006.08.077; PII: S0360-3016(06)02969-5; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ANOXIA; BIOPSY; CARCINOMAS; FAILURES; GROWTH FACTORS; HEALTH HAZARDS; MORTALITY; PATIENTS; PROSTATE; RADIOTHERAPY

Citation Formats

Green, Melanie M.L., Academic Department of Radiation Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, Hiley, Crispin T., Shanks, Jonathan H., Bottomley, Ian C., West, Catharine, Cowan, Richard A., and Stratford, Ian J. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. United States: N. p., 2007. Web. doi:10.1016/j.ijrobp.2006.08.077.
Green, Melanie M.L., Academic Department of Radiation Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, Hiley, Crispin T., Shanks, Jonathan H., Bottomley, Ian C., West, Catharine, Cowan, Richard A., & Stratford, Ian J. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. United States. doi:10.1016/j.ijrobp.2006.08.077.
Green, Melanie M.L., Academic Department of Radiation Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, Hiley, Crispin T., Shanks, Jonathan H., Bottomley, Ian C., West, Catharine, Cowan, Richard A., and Stratford, Ian J. Mon . "Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome". United States. doi:10.1016/j.ijrobp.2006.08.077.
@article{osti_20850298,
title = {Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome},
author = {Green, Melanie M.L. and Academic Department of Radiation Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester and Hiley, Crispin T. and Shanks, Jonathan H. and Bottomley, Ian C. and West, Catharine and Cowan, Richard A. and Stratford, Ian J.},
abstractNote = {Purpose: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. Methods and Materials: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score {>=}6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatment diagnostic tumor biopsies using a semiquantitative immunohistochemical scoring system. The results were analyzed in relation to clinicopathologic factors and patient outcome including biochemical failure and disease-specific mortality. Results: High VEGF expression was associated with a poor prognosis: in univariate log rank analysis, VEGF was the only significant prognostic factor for disease-specific survival (p = 0.035). High VEGF expression also associated with increased Gleason score (p = 0.02), but not posttreatment biochemical failure. Conclusion: High tumor expression of VEGF identified patients at high risk of failure of treatment with radiotherapy. These patients might benefit from additional treatment approaches incorporating anti-angiogenic or hypoxia-specific agents.},
doi = {10.1016/j.ijrobp.2006.08.077},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 1,
volume = 67,
place = {United States},
year = {Mon Jan 01 00:00:00 EST 2007},
month = {Mon Jan 01 00:00:00 EST 2007}
}